https://orcid.org/0000-0001-7973-6333
References
- Akgün H, Karamelekoğlu İ, Berk B, Kurnaz I, Sarıbıyık G, Öktem S, Kocagöz T. 2012. Synthesis and antimycobacterial activity of some phthalimide derivatives. Bioorg Med Chem. 20(13):4149–4154.
- Ao M, Xiao X, Ao Y. 2018. Low density lipoprotein modified silica nanoparticles loaded with docetaxel and thalidomide for effective chemotherapy of liver cancer. Braz J Med Biol Res. 51(3):1–6660.
- Bishop CW, Knutson JC, Strugnell S, Mazess RB. 2004. Synthesis and antiproliferative effects of 1α,24(S)-dihydroxyvitamin D2, and use with other agents. US 20040009958.
- Eriksson T, Björkman S, Höglund P. 2001. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol. 57(5):365–376.2.
- Hess S, Akermann MA, Wnendt S, Zwingenberger K, Eger K. 2001. Synthesis and immunological activity of water-soluble thalidomide prodrugs . Bioorg & Med Chem. 9(5):1279–1291.
- Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, et al. 2015. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 523(7559):183–188.,
- Kumar A, Porwal M, Verma A, Mishra AK. 2014. Impact of pomalidomide therapy in multiple myeloma: a recent survey. J Chemotherapy. 26(6):321–327.
- Kyle RA. 2002. Current therapy of multiple myeloma. Intern Med. 41(3):175–180.
- Kyle RA, Rajkumar SV. 2001. Therapeutic application of thalidomide in multiple myeloma. Semin Oncol. 28(6):583–587.
- Liu YB, Huang XG, He X, Zhou YQ, Jiang XG, Selina CK, Jaffrey SR, Xu GQ. 2015. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. Faseb J. 29(12):4829–4839.
- Luzzio FA, Mayorov AV, Ng SSW, Kruger EA, Figg WD. 2003. Thalidomide Metabolites and Analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFalpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine. J Med Chem. 46(18):3793–3799.
- Mccluskey A, Sakoff J, Ackland S. 2002. Protein Phosphate Inhibitors. WO 2002076989.
- McCurdy AR, Lacy MQ. 2013. Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 4(3):211–216.
- Murayama N, Kazuki Y, Satoh D, Arata K, Harada T, Shibata N, Guengerich FP, Yamazaki H. 2017. Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 42(3):343–348.
- Nakamura K, Matsuzawa N, Ohmori S, Ando Y, Yamazaki H, Matsunaga T. 2013. Clinical evidence of pharmacokinetic changes in thalidomide therapy. Drug Metab Pharmacok. 28(1):38–43.
- Nakamura T, Noguchi T, Kobayashi H, Miyachi H, Hashimoto Y. 2006. Mono- and dihydroxylated metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity . Chem Pharm Bull. 54(12):1709–1714.
- Nakamura T, Noguchi T, Miyachi H, Hashimoto Y. 2007. Hydrolyzed metabolites of thalidomide: synthesis and TNF-alpha production-inhibitory activity . Chem Pharm Bull. 55(4):651–654.
- Rajkumar SV. 2001. Thalidomide in the treatment of multiple myeloma. Expert Rev Anticanc Ther. 1(1):20–28.
- Satyanarayana B;M, Krishna P, Ramachndran D. 2011. A novel and efficient synthesis of thalidomide. Int J Chemtech Res. 3(1):234–237.
- Sun GL, Zhang WW, Zhan XP, Liu ZL, Mao ZM. 2014. Synthesis and biological activities of 3-methoxy-6-substituted-5,6-dihydropyrrolo[3,4-b]pyridin-7-ones. Chin J Org Chem. 34(3):546–551.
- Yeh C, B; Lin PY, Hwang JM, Su CJ, Yeh YT, Yang SF, Chou MC. 2012. Study on synthesis of thalidomide analogues and their bioactivities; inhibition on iNOS pathway and cytotoxic effects. Med Chem Res. 21(7):953–963.
- Zhao CK, Li C, Wang XH, Bao YJ, Yang FH, Huang M. 2018. The regio-selective synthesis of 10-hydroxy camptothecin norcantharidin conjugates and their biological activity evaluation in vitro. Roy Soc Open Sci. 5(6):172317
- Zhao CK, Wang XH, Yang FH, Gao L, Wang YH. 2018. A simple route to a novel acid-sensitive 20(S)-O-linked camptothecin norcantharidin acid ester derivative. Roy Soc Open Sci. 5(2):170842
- Zhao CK, Xu L, Wang XH, Bao YJ, Wang YH. 2019. Synthesis of Dual Target CPT-Ala-Nor Conjugates and Their Biological Activity Evaluation. Anti-Cancer Agents Med Chem. 19(4):502–508.
- Zhu X, Giordano T, Yu QS, Holloway HW, Perry TA, Lahiri DK, Brossi A, Greig NH. 2003. Thiothalidomides: Novel Isosteric Analogues of Thalidomide with Enhanced TNF-alpha inhibitory activity. J Med Chem. 46(24):5222–5229.